Radiotherapy plays an important role as a consolidation treatment after systemic therapy, either to shorten the course of systemic therapy and reduce hematological, cardiac and fertility toxicity or to reduce the risk of relapse e.g., for bulky masses. This role has been challenged in recent years partly due to the hope that PET/CT can select patients who benefit from treatment and reduce the number of patients treated and partly due to exaggerated concern about RT long-term effects which are minimal with modern RT. Several studies have looked at the role of PET in guiding the use of RT with mixed success. In most cases, RT still improved disease control even when PET/CT showed complete response. However, population-based studies show continuous decline in use of RT in early-stage lymphoma, primarily driven by medical oncologists/hematologists’ attitudes and concerns. In the last year, there have been several important trial reports confirming the role of consolidation RT or providing good evidence on how to select patients for this treatment, which radiation oncologists need to understand well. This activity discusses the most recent evidence published in the last 12 months including H10, IELSG-37 and UNFOLDER studies.

Topics:

1. Do We Still Need Consolidation RT after IELSG-37 Trial and the Results of PET-Guided RT for PMBCL?
   Umberto Ricardi, MD, PhD
2. Combined Modality Treatment Remains the Gold Standard for Early Hodgkin Lymphoma
   Jessica Louise Brady, ChB, MB
3. Should Consolidation RT for DLBCL be PET-Guided or Based on Baseline Characteristics?
   George Mikhaeel, MD, MBBS
4. Q and A
   Joachim Yahalom, MD, FASTRO - Moderator
   Full Panel

This activity is available from January 7, 2025, through 11:59 p.m. Eastern time on January 6, 2027. 

This activity was originally recorded at the 2024 ASTRO Annual Meeting.